CEL-SCI Corporation (CVM)
CVM Stock Price Chart
Explore CEL-SCI Corporation interactive price chart. Choose custom timeframes to analyze CVM price movements and trends.
CVM Company Profile
Discover essential business fundamentals and corporate details for CEL-SCI Corporation (CVM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 1983
Employees
43.00
Website
https://cel-sci.comCEO
Geert R. Kersten
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
CVM Financial Timeline
Browse a chronological timeline of CEL-SCI Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 12 Jan 2026
Upcoming earnings on 12 Jan 2026
Earnings released on 14 Aug 2025
EPS came in at -$1.36 .
Stock split effective on 20 May 2025
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2025
EPS came in at -$2.40 .
Earnings released on 13 Jan 2025
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%.
Earnings released on 27 Dec 2024
EPS came in at -$0.16 falling short of the estimated -$0.11 by -45.45%.
Earnings released on 14 Aug 2024
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%.
Earnings released on 16 May 2024
EPS came in at -$0.14 matching the estimated -$0.14.
Earnings released on 14 Feb 2024
EPS came in at -$0.14 matching the estimated -$0.14.
Earnings released on 22 Dec 2023
EPS came in at -$0.16 matching the estimated -$0.16.
Earnings released on 11 Aug 2023
EPS came in at -$0.19 falling short of the estimated -$0.17 by -11.76%.
Earnings released on 12 May 2023
EPS came in at -$0.19 falling short of the estimated -$0.17 by -11.76%.
Earnings released on 14 Feb 2023
EPS came in at -$0.18 surpassing the estimated -$0.21 by +14.29%.
Earnings released on 28 Dec 2022
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%.
Earnings released on 15 Aug 2022
EPS came in at -$0.23 falling short of the estimated -$0.15 by -53.33%.
Earnings released on 16 May 2022
EPS came in at -$0.23 falling short of the estimated -$0.16 by -43.75%.
Earnings released on 14 Feb 2022
EPS came in at -$0.20 .
Earnings released on 22 Dec 2021
EPS came in at -$0.19 falling short of the estimated -$0.10 by -90.00%.
Earnings released on 16 Aug 2021
EPS came in at -$0.25 falling short of the estimated -$0.13 by -92.31%.
Earnings released on 18 May 2021
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%.
Earnings released on 16 Feb 2021
EPS came in at -$0.21 .
Earnings released on 30 Dec 2020
EPS came in at -$0.14 , while revenue for the quarter reached $28.56 .
CVM Stock Performance
Access detailed CVM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.